Jeff Bezos's Prometheus secured $12 billion in its second funding round, valuing the physical AI startup at $41 billion as it builds what the company calls an "artificial general engineer" for the physical world. The massive raise signals unprecedented investor confidence in AI systems that can automate heavy engineering and drug design beyond traditional software applications.
Key Takeaways
- Prometheus raised $12B at $41B valuation from JPMorgan Chase, Goldman Sachs, and BlackRock
- The startup targets physical world automation including heavy engineering and drug design
- This marks the company's second major funding round after launching with $6.2B in late 2025
What Happened
Prometheus, co-founded by Amazon founder Jeff Bezos and Vik Bajaj, the former co-founder of Verily (Google's life sciences unit), announced the completion of its $12 billion Series B funding round. The round values the artificial general engineer startup at $41 billion, according to TechCrunch reporting.
The funding came from a consortium led by Bezos himself, along with major financial institutions including JPMorgan Chase, Goldman Sachs, and BlackRock. The company focuses specifically on developing AI systems designed to automate complex physical world tasks, distinguishing it from purely software-based AI applications.
What Is Confirmed
The available reports confirm Prometheus launched in late 2025 with an initial funding round of $6.2 billion, making this its second major capital raise in less than a year. The startup explicitly targets two primary areas: heavy engineering automation and drug design processes.
The company's leadership combines Bezos's experience scaling Amazon's logistics and infrastructure with Bajaj's background in life sciences technology development at Google's Verily division. The specific term "artificial general engineer" appears in the company's positioning, though technical details about the AI system's capabilities remain limited in available reporting.
Why It Matters
The $41 billion valuation represents one of the highest startup valuations for a company focused on physical world AI applications, signaling institutional investor confidence in AI systems that move beyond text, images, and software into manufacturing, construction, and pharmaceutical development. The backing from major financial institutions like JPMorgan Chase and Goldman Sachs suggests mainstream finance views physical AI as a viable investment category.
For the broader AI industry, Prometheus's focus on an "artificial general engineer" concept represents a distinct approach from current AI development trends centered on large language models and consumer applications. The combination of Bezos's operational scaling expertise and Bajaj's life sciences background positions the startup to address industrial automation challenges that require both software intelligence and physical world understanding.
What Remains Unclear
Available reports do not specify the technical architecture behind Prometheus's "artificial general engineer" system or provide details about current development progress. The company has not disclosed specific partnerships with engineering firms, pharmaceutical companies, or manufacturing operations that would demonstrate real-world application of its technology.
The timeline for product deployment, regulatory approvals for drug design applications, and competitive positioning against established automation and robotics companies remain unaddressed in current reporting. The company's hiring plans, research facilities, and technical team composition beyond the co-founders have not been disclosed.
What To Watch Next
Monitor Prometheus for announcements of pilot programs or partnerships with engineering and pharmaceutical companies, which would provide concrete evidence of the AI system's capabilities beyond fundraising milestones. Technical publications or patent filings from the company could reveal more details about the "artificial general engineer" approach and how it differs from existing automation technologies.
Watch for regulatory developments around AI applications in drug design and heavy engineering, as these sectors require safety certifications that could impact Prometheus's deployment timeline. The company's next public communications about specific use cases or customer relationships will indicate whether the substantial funding translates into operational progress in physical world AI applications.
